Abstract

Transcription factors are known to mediate the conversion of somatic cells to induced pluripotent stem cells (iPSCs). Transcription factor TFAP2C plays important roles in the regulation of embryonic development and carcinogenesis; however, the roles of Tfap2c in regulating somatic cell reprogramming are not well understood. Here we demonstrate Tfap2c is induced during the generation of iPSCs from mouse fibroblasts and acts as a facilitator for iPSCs formation. Mechanistically, the c-Myc-dependent apoptosis, which is a roadblock to reprogramming, can be significantly mitigated by Tfap2c overexpression. Meanwhile, Tfap2c can greatly promote mesenchymal-to-epithelial transition (MET) at initiation stage of OSKM-induced reprogramming. Further analysis of gene expression and targets of Tfap2c during reprogramming by RNA-sequencing (RNA-seq) and ChIP-qPCR indicates that TFAP2C can promote epithelial gene expression by binding to their promoters directly. Finally, knockdown of E-cadherin (Cdh1), an important downstream target of TFAP2C and a critical regulator of MET antagonizes Tfap2c-mediated reprogramming. Taken together, we conclude that Tfap2c serves as a strong activator for somatic cell reprogramming through promoting the MET and inhibiting c-Myc-dependent apoptosis.

Details

Title
TFAP2C facilitates somatic cell reprogramming by inhibiting c-Myc-dependent apoptosis and promoting mesenchymal-to-epithelial transition
Author
Wang, Yuan 1 ; Chen, Shuang 1 ; Jiang Qingyuan 2 ; Deng Jie 1 ; Cheng Fuyi 1 ; Lin, Yi 1 ; Cheng, Lin 1 ; Ye Yixin 1 ; Chen, Xiaolei 1 ; Yao Yunqi 1 ; Zhang, Xiaomei 3 ; Shi, Gang 1 ; Dai Lei 1 ; Su Xiaolan 1 ; Peng, Yong 1   VIAFID ORCID Logo  ; Deng Hongxin 1 

 Sichuan University and Collaborative Innovation Center for Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Chengdu, P.R. China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581) 
 Sichuan University and Collaborative Innovation Center for Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Chengdu, P.R. China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581); Sichuan Provincial Hospital for Women and Children, Department of Obstetrics, Chengdu, P.R. China (GRID:grid.13291.38) 
 Sichuan University and Collaborative Innovation Center for Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Chengdu, P.R. China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581); Sichuan University, Laboratory Animal Center, Chengdu, P.R. China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581) 
Publication year
2020
Publication date
Jun 2020
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2417167308
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.